comprehensive -WSS

comprehensive

author：focus 2025-10-06 11:41:30 - browse：793

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： STAT Virtual Event: Putting AI to the Test

Wikipedia

leisure time

WSS

Dario to buy mental health app maker Twill in cash and stock deal

6 phony surgeries that take placebo to the extreme

PBM reform efforts get punted in Congress

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Ukraine and a new approach to mental health in war

Experts study whether long Covid risk adds up with each reinfection

hotspot

comprehensive

explore

Medicare details structure of new drug price negotiation program

Senate HELP committee spars over health care workforce policies

State Dept. review finds Biden bears some blame for Afghanistan failures

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

The cancer drug shortage isn’t new — and neither are the solutions

Alabama hospital puts IVF treatments on hold

Novavax promises a turnaround & Lilly roils the obesity market

A new nitrogen execution bill also undermines medical licensing

Medical leaders decry Supreme Court decision on affirmative action

Antivenom research: Lessons from HIV applied in search for universal antidote

explore

Senate HELP committee spars over health care workforce policies

Alabama IVF ruling threatens families facing fatal genetic disease

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Community Health Systems hospitals under DOJ investigation

Senators: Long

A new nitrogen execution bill also undermines medical licensing

Wikipedia

leisure time

explore

knowledge